Articles and application notes
CAR T cell process development study
Manual, open processing is not ideal for commercial production of chimeric antigen receptor (CAR T) cells. This study describes development of a closed and semi-automated process that can be adapted for GMP compliance and CAR T developers’ needs.
CAR T cells: closed and semi-automated processing
A robust workflow that can be adapted for cGMP compliance in commercial production. Achieves 1 × 1010 expanded T cells in 8 days.
CBMG and Cytiva collaboration
CBMG accelerates cell therapy manufacturing with Cytiva’s start-to-finish FlexFactory for cellular therapies.
Consistent cord blood cryopreservation
Customer study shows reproducible cord blood freezing without liquid nitrogen.
Delivering LN2-free multi-bag cryopreservation
A proof-of-concept study that demonstrates the controlled cooling of large volume biological samples with high and consistent post-thaw recovery. An alternative solution to cryopreserving with liquid nitrogen.
Developments in cell expansion for cell processing
Expand your knowledge on perfusion, our rocking technology and more by reading through our latest papers and posters.
Gene transfer by spinoculation
SpinOculation C-Pro protocol software offers a closed, automated solution for gene transfer by lentiviral transduction in CAR-T cell therapy processing.
Going liquid nitrogen-free for low-impact cryopreservation
Switching to a liquid nitrogen-free controlled-rate freezer can reduce carbon emissions by 87% over 10 yr and decrease operating costs by up to 97%. Read our study to see how you could minimize the environmental impact of your cryopreservation.
Improving viral vector manufacturing
How to prepare for the future of viral vector production to meet the demand generated by gene-modified cell therapies and gene therapies. Based on interview with Phil Vanek.
Interrupted cooling in cryopreservation
How does a power interruption during cooling affect post-thaw cell viability? This study demonstrates minimal effect of power outages and interrupted cooling during cryopreservation when using a VIA Freeze controlled-rate freezer.
Lentiviral vector upstream process
Upstream lentiviral vector process with stable producer cell line that can be adapted for commercial manufacturing. Scales linearly from 5 to 28 L in Xcellerex bioreactors yielding ≥ 1010 TU/L of LV-GFP.
Natural killer cells manufacturing
Workflow for NK cell production from apheresis units. Isolation, xeno-free expansion, harvest, and cryopreservation amenable to GMP manufacturing.
Producing consistent and compliant cell therapies
A new software platform is designed to simplify cell therapy processes. It offers many features and a single digital space to support both consistent production and compliance with regulations such as cGMP.
The Supply Chain Challenge
Overcoming the challenges of manufacturing and administering a complex product to any patient is critical for delivering cell therapies. Here two industry experts provide practical advice on strategies to meet supply chain challenges.
Water free vs water bath cell thawing
Read about this benchmarking study and benefits of dry thawing technology.
AAV production using microcarriers
Large-scale AAV production processes are needed to industrialize gene therapies. This customer case study describes microcarrier culture in a 1 L bioreactor.